Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dna X (SONM) Other Non Operating Income (2018 - 2025)

Historic Other Non Operating Income for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to -$161000.0.

  • Dna X's Other Non Operating Income fell 74736.84% to -$161000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $109000.0, marking a year-over-year increase of 15343.14%. This contributed to the annual value of $246000.0 for FY2024, which is 21495.33% up from last year.
  • Per Dna X's latest filing, its Other Non Operating Income stood at -$161000.0 for Q3 2025, which was down 74736.84% from -$215000.0 recorded in Q2 2025.
  • In the past 5 years, Dna X's Other Non Operating Income registered a high of $601000.0 during Q4 2022, and its lowest value of -$215000.0 during Q2 2025.
  • Over the past 5 years, Dna X's median Other Non Operating Income value was -$59000.0 (recorded in 2023), while the average stood at -$14894.7.
  • As far as peak fluctuations go, Dna X's Other Non Operating Income plummeted by 216666.67% in 2021, and later surged by 4500000.0% in 2024.
  • Over the past 5 years, Dna X's Other Non Operating Income (Quarter) stood at -$40000.0 in 2021, then soared by 1602.5% to $601000.0 in 2022, then tumbled by 100.17% to -$1000.0 in 2023, then surged by 45000.0% to $449000.0 in 2024, then crashed by 135.86% to -$161000.0 in 2025.
  • Its Other Non Operating Income stands at -$161000.0 for Q3 2025, versus -$215000.0 for Q2 2025 and $36000.0 for Q1 2025.